Precision BioSciences Q2 Loss Widens on Non-Cash Warrant Charge; Cash Runway Through 2028
DTIL sits 94% above its 52-week low of $3.53.
Summary
A non-cash warrant liability charge widened Precision BioSciences' Q2 loss, but operating costs declined and the cash runway extends through 2028. Clinical programs for hepatitis B and Duchenne muscular dystrophy continue to advance.
Key Events · Earnings and Guidance · DTIL
-
Q2 Loss Driven by Non-Cash Warrant Charge
Net loss of $32.7M ($1.26/share) includes a $13.9M non-cash loss from warrant liability remeasurement — a mark-to-market adjustment reflecting a higher stock price, not a cash outflow or new dilution.
-
Cash Runway Reaffirmed Through 2028
Ended Q2 with $112.4M in cash, equivalents, and restricted cash. Management expects existing resources and the ATM facility to fund operations and key data milestones through 2028.
-
Operating Expenses Decline 11%
Total operating expenses fell to $19.2M in Q2 2026 from $21.9M a year ago, driven by lower G&A and disciplined R&D spending, even as lead programs advance.
-
PBGENE-HBV Shows Direct cccDNA Elimination
Liver biopsy data from the ELIMINATE-B trial demonstrated a 1-log reduction in cccDNA-derived transcripts after two doses, with less than 1% of cccDNA remaining — the first clinical evidence of direct cccDNA elimination by a gene editor.
Analysis · DTIL · Life Sciences
A $13.9 million non-cash charge from warrant liability remeasurement—a mark-to-market adjustment tied to the stock's rise, not a cash outflow or new dilution—drove Precision BioSciences' Q2 net loss to $32.7 million, or $1.26 per share. Cost discipline was evident as operating expenses fell 11% year-over-year to $19.2 million. The quarter ended with $112.4 million in cash and restricted cash, and management reaffirmed that existing resources and the at-the-market facility extend the cash runway through 2028. On the clinical front, biopsy data from the ELIMINATE-B trial showed PBGENE-HBV directly eliminated cccDNA, while the Phase 1/2 FUNCTION-DMD trial is actively recruiting, with initial safety data expected by year-end 2026.
At the time of this filing, DTIL was trading at $6.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.7M. The 52-week trading range was $3.53 to $9.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.